NeoChord Inc. 07.24.17
NeoChord Inc., a privately-held medical technology company developing minimally invasive valve repair for degenerative mitral regurgitation (DMR), has appointed Andrew ElBardissi, M.D. to its Board of Directors, effective immediately. ElBardissi is replacing Avi Kometz, M.D., as the representative from Deerfield Management on the NeoChord Board of Directors.
“We are pleased to add Andrew to our Board of Directors, and we look forward to his strategic guidance. With his experience in early stage medical technology development, cardiothoracic surgery and research, Andrew will be of great benefit to the company as we continue progress with our U.S. clinical trial,” said David Chung, president and CEO. “Avi has been an integral part of NeoChord over the past few years, and we are thankful for his partnership and many contributions.”
ElBardissi has significant investment experience in the healthcare sector. He is currently an investor on the private transactions team at Deerfield Management Company and has previously held roles as an early stage life-sciences venture investor and investment banker. He received residency training in general surgery at Harvard Medical School’s Brigham and Women’s Hospital and in Cardiothoracic Surgery at Stanford University. ElBardissi has been independently funded by the National Institutes of Health and the Agency for Healthcare Research and Quality, has over 30 publications in leading peer reviewed scientific journals, and as presented his research at numerous medical and surgical conferences.
“I am delighted to join an organization leading the way in minimally invasive treatment of structural heart disease,” said ElBardissi, “I am looking forward to providing guidance as a member of the Board of Directors as the company continues to excel with their clinical, commercial and R&D programs."
Founded in 2007 and based in St. Louis Park, Minn., NeoChord’s DS1000 system received CE market clearance in December 2012. NeoChord received IDE approval from the U.S. Food and Drug Administration for the U.S. pivotal trial in May 2016.
“We are pleased to add Andrew to our Board of Directors, and we look forward to his strategic guidance. With his experience in early stage medical technology development, cardiothoracic surgery and research, Andrew will be of great benefit to the company as we continue progress with our U.S. clinical trial,” said David Chung, president and CEO. “Avi has been an integral part of NeoChord over the past few years, and we are thankful for his partnership and many contributions.”
ElBardissi has significant investment experience in the healthcare sector. He is currently an investor on the private transactions team at Deerfield Management Company and has previously held roles as an early stage life-sciences venture investor and investment banker. He received residency training in general surgery at Harvard Medical School’s Brigham and Women’s Hospital and in Cardiothoracic Surgery at Stanford University. ElBardissi has been independently funded by the National Institutes of Health and the Agency for Healthcare Research and Quality, has over 30 publications in leading peer reviewed scientific journals, and as presented his research at numerous medical and surgical conferences.
“I am delighted to join an organization leading the way in minimally invasive treatment of structural heart disease,” said ElBardissi, “I am looking forward to providing guidance as a member of the Board of Directors as the company continues to excel with their clinical, commercial and R&D programs."
Founded in 2007 and based in St. Louis Park, Minn., NeoChord’s DS1000 system received CE market clearance in December 2012. NeoChord received IDE approval from the U.S. Food and Drug Administration for the U.S. pivotal trial in May 2016.
